alternatives — when to consider switching
If isn't working as expected, isn't covered by your insurance, side effects are intolerable, or you want to try something with different efficacy profile, several FDA-approved alternatives exist within the GLP-1 family. This page compares each on efficacy, dosing schedule, cost, and switching considerations.
The GLP-1 family — your alternatives
Single GLP-1 receptor agonists
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss, Rybelsus oral) — Novo Nordisk
- Liraglutide (Victoza for diabetes, Saxenda for weight loss) — Novo Nordisk
- Dulaglutide (Trulicity for diabetes) — Eli Lilly
- Exenatide (Byetta, Bydureon for diabetes) — AstraZeneca
Dual GIP/GLP-1 receptor co-agonists
- Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — Eli Lilly
Efficacy comparison — at-a-glance
Mean body-weight reduction in pivotal trials (higher = more weight loss):
- Tirzepatide (Mounjaro / Zepbound): ~22.5% at 72 weeks (SURMOUNT-1)
- Semaglutide 2.4mg (Wegovy): ~14.9% at 68 weeks (STEP-1)
- Semaglutide 1.0mg (Ozempic): ~6-8% at 68 weeks (varies by trial)
- Liraglutide 3.0mg (Saxenda): ~8% at 56 weeks (SCALE)
- Dulaglutide (Trulicity): ~3-5% (not a weight-loss-specific indication)
Dosing frequency comparison
- Once weekly: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Bydureon
- Once daily: Saxenda, Victoza
- Twice daily: Byetta (older formulation)
- Oral (daily): Rybelsus
Switching considerations
Switching within the same active ingredient
Switching between Mounjaro ↔ Zepbound (both tirzepatide), or Ozempic ↔ Wegovy (both semaglutide), or Victoza ↔ Saxenda (both liraglutide), is straightforward because the active ingredient is identical. The main differences are dose (Wegovy goes to 2.4mg vs Ozempic max ~2mg) and labeled indication (weight loss vs diabetes). Prescribers can transition without dose reset.
Switching between different active ingredients
Switching from semaglutide → tirzepatide (or vice versa), or to/from liraglutide, typically requires restarting titrationfrom the new drug's lowest dose. This is because:
- Different doses correspond to different molecular potencies
- Tolerability differs — even if you tolerated full-dose semaglutide, you may need to titrate up on tirzepatide
- Insurance coverage often requires fresh prior authorization for the new drug